Caption: Kaushik J. Dave, Ph.D., President and CEO of Actinium, stated, "The FDA's decision to grant orphan-drug status for Actimab-A is a significant milestone for the Company and recognizes the need for innovative new approaches to treat AML. The desig
Credit: Actinium Pharmaceuticals, Inc.